A 6 month randomized, double blind, placebo controlled, multi-center trial of high dose atorvastatin on myocardial perfusion abnormalities by positron emission tomography in coronary artery disease

American Heart Journal

Volumn 155, Issue 2, 2008, Pages 245-253

  Sdringola, Stefano ^a   Gould, K Lance ^a   Zamarka, Linda Guilds ^b   McLain, Richard ^b   Garner, Jennifer ^b  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE; AMMONIA N 13; ATORVASTATIN; DIPYRIDAMOLE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; RUBIDIUM 82;

ADULT; AGED; ARTICLE; AUTOMATION; CLINICAL TRIAL; COMPUTER PROGRAM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DISEASE SEVERITY; DOUBLE BLIND PROCEDURE; DRUG MEGADOSE; FOLLOW UP; HEART MUSCLE PERFUSION; HUMAN; IMAGE ANALYSIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; STRESS; TREATMENT RESPONSE; UNITED STATES; UNIVERSITY HOSPITAL;

ADULT; AGED; AGED, 80 AND OVER; CORONARY ARTERY DISEASE; CORONARY CIRCULATION; CORONARY VESSELS; DOUBLE-BLIND METHOD; HEART; HEPTANOIC ACIDS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MIDDLE AGED; MYOCARDIAL ISCHEMIA; POSITRON-EMISSION TOMOGRAPHY; PROSPECTIVE STUDIES; PYRROLES;

EID: 38349065076     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2007.10.025     Document Type: Article

References (14)

1. Gould K.L., Martucci J.P., Goldberg D.I., et al. Short-term cholesterol lowering decreases size and severity of perfusion abnormalities by Positron Emission Tomography after dipyridamole in patients with coronary artery disease. A potential noninvasive marker of healing coronary endothelium. Circulation 89 (1994) 1530-1538
2. Gould K.L., Ornish D., Scherwitz L., et al. Changes in myocardial perfusion abnormalities by positron emission tomography after long-term, intense risk factor modification. JAMA 274 (1995) 894-901
3. Gould K.L., Nakagawa Y., Nakagawa N., et al. Frequency and clinical implications of fluid dynamically significant diffuse coronary artery disease manifest as graded, longitudinal, base to apex, myocardial perfusion abnormalities by non-invasive positron emission tomography. Circulation 101 (2000) 1931-1939
4. Loghin C., Sdringola S., and Gould K.L. Common artifacts in PET myocardial perfusion images due to attenuation-emission misregistration: clinical significance, causes and solutions. J Nucl Med 45 (2004) 1029-1039
5. Nakagawa Y., Nakagawa K., Sdringola S., et al. A precise three dimensional atlas of myocardial perfusion correlation with coronary arteriographic anatomy. J Nucl Cardiol 8 (2001) 580-590
6. Sdringola S., Nakagawa K., Nakagawa Y., et al. Combined intense lifestyle and pharmacologic lipid treatment further reduce coronary events and myocardial perfusion abnormalities compared to usual care cholesterol lowering drugs in coronary artery disease. J Am Coll Cardiol 41 (2003) 262-272
7. Sdringola S., Boccalandro F., Loghin C., et al. Mechanisms of progression and regression of coronary artery disease by PET related to treatment intensity and clinical events at long-term follow-up. J Nucl Med 47 (2006) 59-67
8. Ling M.C., Ruddy T.D., deKemp R.A., et al. Early effects of statin therapy on endothelial function and microvascular reactivity in patients with coronary artery disease. Am Heart J 149 (2005) 1137
9. Janatuinen T., Knuuti J., Toikka J.O., et al. Effect of pravastatin on low-density lipoprotein oxidation and myocardial perfusion in young adults with type 1 diabetes. Arterioscler Thromb Vasc Biol 24 (2004) 1303-1308
10. Huggins G.S., Pasternak R.C., Alpert N.M., et al. Effects of short-term treatment of hyperlipidemia on coronary vasodilator function and myocardial perfusion in regions having substantial impairment of baseline dilator reverse. Circulation 98 (1998) 1291-1296
11. Baller D., Notohamiprodjo G., Gleichmann U., et al. Improvement in coronary flow reserve determined by positron emission tomography after 6 months of cholesterol-lowering therapy in patients with early stages of coronary atherosclerosis. Circulation 99 (1999) 2871-2875
12. Yokoyama I., Yonekura K., Inoue Y., et al. Long-term effect of simvastatin on the improvement of impaired myocardial flow reserve in patients with familial hypercholesterolemia without gender variance. J Nucl Cardiol 8 (2001) 445-451
13. Guethlin M., Kasel A.M., Coppenrath K., et al. Delayed response of myocardial flow reserve to lipid-lowering therapy with fluvastatin. Circulation 99 (1999) 475-481
14. Wielepp P., Baller D., Gleichmann U., et al. Beneficial effects of atorvastatin on myocardial regions with initially low vasodilatory capacity at various stages of coronary artery disease. Eur J Nucl Med Mol Imaging 32 (2005) 1371-1377